[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"steatohepatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:steatohepatitis":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,61,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100629594","expanded-studies-on-the-scapis-stockholm-reexamination-cohort-100629594",false,"NCT07476703","Expanded Studies on the SCAPIS Stockholm Reexamination Cohort","Expanded Studies of Risk Factors for Pulmonary-, Liver-, and Cardiovascular Disease in the SCAPIS 2 Stockholm Reexamination","SCAPIS-ReEx","Inclusion Criteria: Subjects already included in the main \u002F general SCAPIS reexamination study in Stockholm.\n\nExclusion Criteria: Inability to provide consent.",true,"ALL","56 Years","74 Years",{"count":22,"type":23},1400,"ESTIMATED","OBSERVATIONAL","The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018. The study is a collaborative effort among six university hospitals across Sweden. A follow-up study, SCAPIS 2, is conducted for half of the original participants. In Stockholm, 2,500 individuals will be re-examined at Danderyd University Hospital and Karolinska Institutet.\n\nSCAPIS 2 includes a core set of examinations involving blood sampling, questionnaires, and imaging. In addition to these, complementary local investigations are conducted to enable more detailed research questions. This protocol describes the additional studies conducted in the Stockholm cohort. All complementary assessments aim to identify risk factors for current and future lung, liver, and cardiovascular diseases.:\n\nEXTENDED SAMPLING: Saliva and Blood Samples with Blood Cell Isolation. EXTENDED QUESTIONNAIRES: Dyspnea, Sleep, Respiratory Infections, and Dental Health.\n\nEXTENDED IMAGING AND PHYSIOLOGICAL MEASUREMENTS Cardiac Ultrasound and Abdominal Aortic Measurements. Liver Elastography. Vascular Stiffness by cuff-based pulse wave analysis and Photoplethysmography (PPG). Valvular and Vascular Calcification by CT imaging.",[27,28,29,30,31,32,33,34,35,36,37,38],"Coronary Artery Disease","Arterial Stiffness, Blood Pressure","AORTIC VALVE DISEASES","Mitral Valve Stenosis and\u002For Insufficiency","Heart Failure","Pulmonary Disease, Chronic Obstructive (COPD)","Steatohepatitis","Inflammation Biomarkers","Lipid Profile","Oral Microbiota","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Associated-dysfunction Steatohepatitis (MASH)",[40,41,42,43,44,45,46,47],"coronary artery disease","arterial stiffness","MASLD","COPD","inflammation","dyslipidemia","aortic aneurysm","oral microbiota","RECRUITING","2026-03-12",{"date":51,"type":52},"2026-03-17","ACTUAL",{"date":54,"type":52},"2024-04-08",{"date":56,"type":23},"2026-08-30",{"name":58,"class":59},"Danderyd Hospital","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":18,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":60},"100612511","diagnosis-and-quantification-of-hepatic-steatosis-using-near-infrared-spectroscopy-100612511","NCT07254533","Diagnosis and Quantification of Hepatic Steatosis Using Near-infrared Spectroscopy","STEATO-NIR","Inclusion Criteria:\n\nLiver grafts:\n\n* Men or women aged 18 and over\n* All donors accepted by the MA4FC procurement team, including brain-dead donors and Maastricht 3 donors, even if placed on a perfusion machine\n* Donors whose families have received information about the study and have not expressed any opposition\n\nSurgical specimens (hepatectomy):\n\n* Men or women aged 18 years and older\n* Subjects who have undergone surgery for any indication of hepatectomy\n* Affiliated with social security,\n* Having received information about the study and not having expressed opposition\n\nExclusion Criteria:\n\nLiver grafts:\n\n* Donors whose liver will be subject to a SPLIT procedure\n* Donors for whom there is a medical-legal obstacle\n* Donors whose family or loved ones oppose scientific sampling: The hospital coordination team will consult the national refusal register and question loved ones to determine whether the deceased would have opposed sampling. If the donor and\u002For family oppose scientific sampling, then sampling will not be performed.\n\nSurgical specimens (hepatectomy):\n\n* Subjects covered by Articles L1121-5 to 1121-8 of the Public Health Code (minors, adults under guardianship or curatorship, patients deprived of their liberty, pregnant or breastfeeding women),\n* Subjects who do not understand the French language","18 Years",{"count":70,"type":23},90,"INTERVENTIONAL",[73],"NA","In liver transplantation, the main problem is the shortage of grafts due to the small pool of donors. In order to increase the number of donors, grafts are increasingly being taken from older donors, known as 'expanded criteria' donors, who have liver steatosis lesions. Currently, expanded criteria donors account for 75% of liver transplants, whereas in 2009 they accounted for less than 30% of liver transplants.\n\nSteatosis and its progression Non-alcoholic steatohepatitis (NASH) is an emerging disease in industrialised countries due to obesity, and corresponds to the accumulation of intracytoplasmic triglycerides.\n\nSteatosis is diagnosed when this fat content represents more than 5% of the total liver mass. There are two types of steatosis: microvesicular steatosis and macrovacuolar steatosis, defined by the presence of lipid droplets larger than the nucleus with a nucleus displaced to the periphery. Macrovacuolar steatosis is responsible for impaired liver function if it is present in ≥30% of hepatocytes. It is a factor in poor prognosis for liver transplants, with reduced graft and recipient survival and an increase in early graft dysfunction after liver transplantation. The quantification of hepatic steatosis is based on the pathological analysis of a liver biopsy, which is currently the gold standard.\n\nThis technique has disadvantages: it is an invasive method, requiring an experienced pathologist, and presents inter-individual variability in the assessment and quantification of steatosis.\n\nIt is therefore essential to develop new non-invasive diagnostic tools that can identify the presence of steatosis \\> 5% and ≥ 30%. Several non-invasive techniques for diagnosing steatosis have been studied: Fibroscan, CT scan, MRI, but none of those studied previously allow for the accurate quantification of hepatic steatosis, particularly macrovacuolar steatosis, with instant results.",[76,33],"Hepatic Transplantation","NOT_YET_RECRUITING","2025-11-25",{"date":80,"type":52},"2025-11-28",{"date":82,"type":23},"2026-01",{"date":84,"type":23},"2027-01",{"name":86,"class":59},"Assistance Publique Hopitaux De Marseille",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":18,"minAge":68,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":71,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100488502","endoscopic-ultrasound-guided-large-diameter-lumen-apposing-metal-stent-gastro-gastrostomy-for-bypass-reversal-in-patients-with-roux-en-y-gastric-bypass-100488502","NCT05640947","Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass","Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass: a Proof of Concent Study","LABOR","Inclusion Criteria:\n\n* Group 1) patients needing any kind of parenteral nutritional support (eg. hypo- albuminemia, hypovitaminoses, mineral deficiencies,...) that can not be corrected by dietary intervention\u002Foral supplementation\n* Group 2) patients with persistent invalidating symptomatic dumping syndrome despite optimal dietary intervention (typical complaints are headache, sweating, trembling, weakness and feeling hungry).\n* Group 3) patients with a refractory marginal ulcers with stenosis of the gastrojejunostomy leading to feading difficulties.\n* Group 4) patients with F3 or F4 liver fibrosis and a tendency to decompensation after bypass surgery, as demonstrated by an increase in serum bilirubin\u002FINR and\u002For lowering of serum albumin.\n\nExclusion Criteria:\n\n1. Uncorrectable coagulopathy\n2. Presence of significant portal hypertension as demonstrated by 2.1) the presence of esophageal and\u002For gastric varices AND\u002FOR 2.2) a hepatic venous pressure gradient (if measured) equal to or more than 10mm Hg AND\u002FOR 2.3) the combination of\n\n   1. a platelet count \\\u003C150000\u002Fµl AND\n   2. liver stiffness measured by elastometry equal to or more than 20 kPa (Baveno guidelines).\n3. Pregnant women, breastfeeding women or women that can not assure adequate anticonception for the duration of the study (based on anamnesis).\n4. Karnofsky index less than 60\n5. Vulnerable patients",{"count":96,"type":23},20,[73],"The primary objective of this open-label pilot study is to investigate whether an endoscopically placed lumen apposing metal stent is an effective alternative to surgery in patients that have a clear indication for reversal of their gastric bypass.",[100,101,33,102,103],"Hypoglycemia","Gastric Outlet Obstruction","Parenteral Support","Gastric Bypass","2025-10-03",{"date":106,"type":52},"2025-10-08",{"date":108,"type":52},"2023-01-30",{"date":110,"type":23},"2028-02",{"name":112,"class":59},"University Hospital, Ghent",2]